LCTX | Lineage cell therapeutics inc - Stock Value & PE Ratio Analysis

3

24

15

Good Growth

AI analysis rates LCTX with a higher value score of 4.
It is mainly due to stable revenue growth, along with adequate safety shown in the balance sheet.
Over the past 3 months, LCTX has maintained a consecutive value rating of 4.0, close to the rating of 3.6 over the past 3 years, indicating stable enterprise value.
Compared to all stocks in the Health Care sector, LCTX has a higher value rating.

LCTX Value Reference Factors

The Value score is derived from various data and factor information, integrated through AI algorithms. The following factors are part of the evaluation used by AI value scores.

Update to 2025/03/15 (Weekly Update)

LCTX Financial Forecast

Unit : USD

Update to 2025/5/9 (Quarterly Update)

LCTX Earnings Table

Unit : USD

QTR	Non-GAAP EPS	EPS YoY	EPS Surprise %	Sales	Sales YoY	Sales Surprise %	NPM
Current	-0.01	66.7%	-75%	2.87M	37.4%	110.7%	-80.3%
2024Q2	-0.02	50%	53.5%	3.78M	203.3%	133.1%	-409.1%
2024Q1	-0.03	0%	34.8%	1.41M	-56.3%	45.2%	-453%
2023Q4	-0.04	-33.3%	4.4%	1.44M	-39.5%	6.2%	-228.7%
2023Q3	-0.03	0%	-57.1%	2.09M	9%	59.4%	-570.6%

Update to 2025/5/9 (Quarterly Update)

LCTX Historical Value Score

You can use historical scores of 3 or above to observe potential performance and make investment decisions.

LCTX Value Strategy Backtest

The following backtest is based on specified rules since 2007. Price chart shows buy/sell time, cumulative returns, and backtesting statistics.

Entry

Exit

The Backtest Result of LCTX from 2007/01 till Now

10.57%
Cumulative Return: 0.55%
Annual Return: 63.87%
Volatility: 0.01
Sharpe Ratio

Statistics data for entering at or above a Value score of 4 and exiting at or below a Value score of 2 from January, 2007 to May, 2025. (Total Trades: 3)